Drug Trial Radar · NCT06582277
Safety and Immunogenicity of Two Dose Levels of OVX836 Influenza Vaccine as a Booster on Participants Previously Administered With OVX836
Last checked: Nov 19, 2026Latest source record: Jun 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
117
Actual
Start
Oct 22, 2024
Primary completion
Jun 2, 2025
Study completion Jun 2, 2025
Sponsor
- Lead sponsor
- OsivaxIndustry
- Sponsor type
- Industry
- Collaborators
- Harmony Clinical Research BVBA; Clinfidence; Inferential; University Hospital, Ghent; KCAS Bio
- First posted
- Sep 3, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 20 years, up to 64 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This phase 2a is designed to evaluate the anamnestic response of a booster dose (either 180 µg or 480 µg) of OVX836 influenza vaccine administered intramuscularly to participants vaccinated three to five years ago in OVX836-002 or OVX836-003 studies. Participants who had received a placebo or Influvac Tetra® in previous studies would serve as controls and would receive the highest dose of OVX836 vaccine (480 µg) as a primary vaccination.
Conditions
- Vaccine-Preventable Diseases
- Influenza
Interventions
OVX836 shotBiological
One single administration intramuscularly at Day 1.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety evaluation of OVX836 (180µg and 480µg)Time frame: From enrollment to the end of trial at 180 days.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Centre for Vaccinology (CEVAC) Ghent University Hospital
Ghent, Belgium
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.